^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Aramchol (aramchol meglumine)
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Galmed, Weizmann Institute of Science
Drug class:
Cholesterol absorption inhibitor, Stearoyl CoA desaturase inhibitor
Related drugs:
14d
The SCD1 inhibitor aramchol interacts with regorafenib and metformin to kill tumor cells. (PubMed, Oncotarget)
Knock down of SCD1 enhanced the percentage of dead cells in vehicle control treated cells but did not alter the abilities of drugs to kill tumor cells. Our data demonstrates that UM cells are killed by treatment with aramchol plus regorafenib plus metformin via enhanced autophagic flux and that this combination may have the potential to control UM tumors that have metastasized to the liver.
Journal
|
ATG5 (Autophagy Related 5) • BECN1 (Beclin 1) • LAMP2 (Lysosomal Associated Membrane Protein 2) • SCD (Stearoyl-CoA Desaturase)
|
Stivarga (regorafenib) • metformin • Aramchol (aramchol meglumine)
1m
Single and Multiple Dose Pharmacokinetics (PK) of Aramchol From an Aramchol Meglumine Tablet (clinicaltrials.gov)
P1, N=32, Recruiting, Galmed Pharmaceuticals Ltd | Not yet recruiting --> Recruiting
Enrollment open
|
Aramchol (aramchol meglumine)
5ms
Novel MAFG-METTL14-SCD1 axis regulates lipid metabolism mediating choroidal melanoma distant metastasis. (PubMed, J Exp Clin Cancer Res)
Our study identifies SCD1-mediated lipid remodeling as a key driver of enhanced membrane fluidity and metastatic potential in CM. Inhibition of SCD1 increases lipid saturation, reduces membrane fluidity, induces oxidative stress, and suppresses liver and lung metastasis. The MAFG-METTL14-SCD1 axis thus represents a critical regulator of CM progression, and combined therapeutic targeting with aramchol and S-HFD offers promising translational potential.
Journal
|
METTL14 (Methyltransferase 14)
|
Aramchol (aramchol meglumine)
5ms
Single and Multiple Dose Pharmacokinetics (PK) of Aramchol From an Aramchol Meglumine Tablet (clinicaltrials.gov)
P1, N=32, Not yet recruiting, Galmed Pharmaceuticals Ltd
New P1 trial
|
Aramchol (aramchol meglumine)
5ms
Comparing The PK Of Aramchol Meglumine Granules To Aramchol Free Acid Tablets (clinicaltrials.gov)
P1, N=16, Active, not recruiting, Galmed Pharmaceuticals Ltd | Trial completion date: May 2025 --> Dec 2025
Trial completion date
|
Aramchol (aramchol meglumine)
6ms
Targeting Stearoyl-CoA Desaturase‑1 (SCD1) by the Drug-Nutraceutical Combination of Montelukast and Bixin in Ameliorating Steatotic NAFLD. (PubMed, ACS Omega)
The combination treatment showed a significant reduction of 21.64% (P < 0.05) in lipid accumulation relative to individual treatment with Bixin or Montelukast and was comparable with the reference drug Aramchol (21.83%). The markers of oxidative stress were also significantly reduced (P < 0.05), evidenced by decreased MDA (42.25%), RNS levels (32.59%), and ROS levels (30.72%) in the combination group. These findings suggest that Bixin and Montelukast in combination hold potential for managing the multiple aspects in the pathophysiology of NAFLD development and progression.
Journal
|
SCD (Stearoyl-CoA Desaturase)
|
Aramchol (aramchol meglumine)
8ms
The SCD1 inhibitor aramchol interacts with regorafenib to kill GI tumor cells in vitro and in vivo. (PubMed, Oncotarget)
Aramchol interacted with the multi-kinase inhibitors sorafenib, regorafenib or lenvatinib, to kill GI tumor cells, with regorafenib exhibiting the greatest effect. Knock down of Beclin1 reduced the lethality of regorafenib and aramchol as single agents and when combined whereas knock down of LAMP2 or BID did not reduce killing caused by aramchol as a single agent but did reduce the lethality of regorafenib alone and regorafenib plus aramchol. In vivo using the HuH7 adult hepatoma cell line, regorafenib and aramchol interacted to suppress tumor growth without normal tissue toxicities.
Preclinical • Journal
|
HSPA5 (Heat Shock Protein Family A (Hsp70) Member 5) • AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1) • ATG16L1 (Autophagy Related 16 Like 1) • BECN1 (Beclin 1) • LAMP2 (Lysosomal Associated Membrane Protein 2) • SCD (Stearoyl-CoA Desaturase)
|
sorafenib • Lenvima (lenvatinib) • Stivarga (regorafenib) • Aramchol (aramchol meglumine)
10ms
A Study Evaluating the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Primary Sclerosing Cholangitis (clinicaltrials.gov)
P2, N=0, Withdrawn, Galmed Pharmaceuticals Ltd | N=24 --> 0 | Suspended --> Withdrawn
Enrollment change • Trial withdrawal
|
Aramchol (aramchol meglumine)
1year
Comparing The PK Of Aramchol Meglumine Granules To Aramchol Free Acid Tablets (clinicaltrials.gov)
P1, N=16, Active, not recruiting, Galmed Pharmaceuticals Ltd | Not yet recruiting --> Active, not recruiting | Trial primary completion date: Jan 2025 --> May 2025
Enrollment closed • Trial primary completion date
|
Aramchol (aramchol meglumine)
over1year
Comparing The PK Of Aramchol Meglumine Granules To Aramchol Free Acid Tablets (clinicaltrials.gov)
P1, N=16, Not yet recruiting, Galmed Pharmaceuticals Ltd | Initiation date: Oct 2024 --> Jan 2025
Trial initiation date
|
Aramchol (aramchol meglumine)
over1year
A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR) (clinicaltrials.gov)
P3, N=157, Suspended, Galmed Research and Development, Ltd. | N=2000 --> 157
Enrollment change
|
Aramchol (aramchol meglumine)
over1year
A Study Evaluating the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Primary Sclerosing Cholangitis (clinicaltrials.gov)
P2, N=24, Suspended, Galmed Pharmaceuticals Ltd | Trial completion date: Dec 2026 --> Dec 2027 | Not yet recruiting --> Suspended | Trial primary completion date: Sep 2025 --> Sep 2026
Trial completion date • Trial suspension • Trial primary completion date
|
Aramchol (aramchol meglumine)
Share via
